Panaxia receives marketing permit for medical cannabis products in Germany

Panaxia receives marketing permit for medical cannabis products in Germany

16-11-2020 15:37:00 | Door: Pie Kamau | Hits: 632 | Tags:

The Israeli subsidiary of Panaxia Global, Panaxia Israel, Israel's largest medical cannabis manufacturer and Neuraxpharm, its partner, Europe's largest pharmaceutical company in the field of the central nervous system (CNS), announced the completion of the registration process and receipt of final regulatory approval from the health authorities in GermanyEurope's largest and fastest-growing cannabis market, for the marketing and distribution of a line of medical cannabis premium products. The products will be marketed in Germany under the brand name, Naxiva-Panaxol.

The Naxiva-Panaxol product line is produced by Panaxia according to EU-GMP, with strict medical and scientific standards, high quality and a fixed dose of active substances in each type of product.  Panaxia is the first Israeli company to receive a marketing permit for medical cannabis products in Germany.

This approval permits Neuraxpharm, Panaxia's strategic partner, to market the products in Germany to physicians who are authorized to issue patients prescriptions for medical cannabis products for treatment of a large number of diseases such as fibromyalgia, PTSD, chronic pain, cancer, and more.

panaxia.co.il

 


Join the Marketing Report Group on LinkedIn!